Healthy Adult Subjects

11
Pipeline Programs
7
Companies
19
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
11
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
3 programs
3
CBP-174Phase 11 trial
CBP-307Phase 11 trial
Test drugPhase 11 trial
Active Trials
NCT04811469CompletedEst. May 2022
NCT05040113CompletedEst. Oct 2021
NCT05917782CompletedEst. Oct 2023
Biogen
BiogenCAMBRIDGE, MA
2 programs
2
BIIB118Phase 11 trial
OmaveloxolonePhase 15 trials
Active Trials
NCT02691702Completed97Est. Jan 2017
NCT07019064Completed52Est. Aug 2025
NCT06054893Recruiting35Est. Nov 2030
+3 more trials
Fulcrum Therapeutics
2 programs
2
FTX-6058/placebo oral capsulePhase 11 trial
Losmapimod 15 mg oral tabletPhase 11 trial
Active Trials
NCT04586985CompletedEst. Nov 2022
NCT05002231CompletedEst. Oct 2021
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
2
Methylnaltrexone bromidePhase 11 trial
methylnaltrexonePhase 11 trial
Active Trials
NCT01366326CompletedEst. Aug 2010
NCT01366378CompletedEst. Feb 2007
Alvotech
AlvotechLUXEMBOURG, Luxembourg
1 program
1
AVT05Phase 11 trial
Active Trials
NCT05632211Completed336Est. Oct 2023
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
PegilodecakinPhase 13 trials
Active Trials
NCT04194892Completed12Est. Mar 2018
NCT03381547Completed12Est. Feb 2018
NCT03267732Completed24Est. Oct 2017
Thea Pharma
Thea PharmaMA - Waltham
1 program
T2309N/A1 trial
Active Trials
NCT04596605CompletedEst. Mar 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
BiogenOmaveloxolone
BiogenOmaveloxolone
Connect BiopharmaTest drug
BiogenOmaveloxolone
BiogenOmaveloxolone
AlvotechAVT05
Connect BiopharmaCBP-307
Fulcrum TherapeuticsLosmapimod 15 mg oral tablet
Connect BiopharmaCBP-174
Fulcrum TherapeuticsFTX-6058/placebo oral capsule
BiogenOmaveloxolone
BiogenOmaveloxolone
Eli Lilly and CompanyPegilodecakin
Eli Lilly and CompanyPegilodecakin
Eli Lilly and CompanyPegilodecakin

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 711 patients across 19 trials

NCT07019064BiogenOmaveloxolone

A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55

Start: Jun 2025Est. completion: Aug 202552 patients
Phase 1Completed
NCT06054893BiogenOmaveloxolone

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

Start: Jul 2024Est. completion: Nov 203035 patients
Phase 1Recruiting

A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

Start: Jul 2023Est. completion: Oct 2023
Phase 1Completed
NCT05927649BiogenOmaveloxolone

A TQTc Study for Omaveloxolone

Start: Jul 2023Est. completion: Sep 202330 patients
Phase 1Completed
NCT05909644BiogenOmaveloxolone

An Open-label DDI Study of Omaveloxolone in Healthy Subjects

Start: Jul 2023Est. completion: Aug 202320 patients
Phase 1Completed

A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants

Start: Dec 2022Est. completion: Oct 2023336 patients
Phase 1Completed

A Study On Human Mass Balance And Biotransformation

Start: Sep 2021Est. completion: Oct 2021
Phase 1Completed
NCT05002231Fulcrum TherapeuticsLosmapimod 15 mg oral tablet

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Start: Aug 2021Est. completion: Oct 2021
Phase 1Completed

Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults

Start: May 2021Est. completion: May 2022
Phase 1Completed
NCT04586985Fulcrum TherapeuticsFTX-6058/placebo oral capsule

Safety, Tolerability and Pharmacokinetics of FTX-6058

Start: Oct 2020Est. completion: Nov 2022
Phase 1Completed
NCT04008186BiogenOmaveloxolone

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

Start: Jun 2019Est. completion: Aug 201961 patients
Phase 1Completed
NCT03664453BiogenOmaveloxolone

A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers

Start: Oct 2018Est. completion: Nov 201832 patients
Phase 1Completed

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

Start: Jan 2018Est. completion: Mar 201812 patients
Phase 1Completed

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Start: Dec 2017Est. completion: Feb 201812 patients
Phase 1Completed

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Start: Sep 2017Est. completion: Oct 201724 patients
Phase 1Completed

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

Start: Mar 2016Est. completion: Jan 201797 patients
Phase 1Completed
NCT01366326Bausch HealthMethylnaltrexone bromide

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

Start: Jul 2010Est. completion: Aug 2010
Phase 1Completed
NCT01366378Bausch Healthmethylnaltrexone

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

Start: Jan 2007Est. completion: Feb 2007
Phase 1Completed

Gastrointestinal Tolerance Assessment of T2309

Start: Jul 2020Est. completion: Mar 2021
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 711 patients
7 companies competing in this space